XENE - Xenon Pharmaceuticals Inc
IEX Last Trade
40.32
0.020 0.050%
Share volume: 229,795
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$40.30
0.02
0.05%
View ratios
Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | |
---|---|---|---|---|---|---|---|
Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | |
Report Date | 2022-05-10 | 2022-08-09 | 2022-11-08 | 2023-03-01 | 2023-05-09 | 2023-08-09 | |
Total revenue | 8.766 M | 536.000 K | 132.000 K | 0.000 | 0.000 | 0.000 | |
Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Gross profit | 8.766 M | 536.000 K | 132.000 K | 0.000 | 0.000 | 0.000 | |
-93.89% | -75.37% | -100.00% | nan% | nan% | |||
Operating expenses | 26.135 M | 30.851 M | 38.260 M | 43.331 M | 49.051 M | 55.624 M | |
Selling general and admin | 6.775 M | 8.705 M | 8.829 M | 8.501 M | 9.535 M | 11.584 M | |
Research and development | 19.360 M | 22.146 M | 29.431 M | 34.830 M | 39.516 M | 44.040 M | |
Total expenses | 26.135 M | 30.851 M | 38.260 M | 43.331 M | 49.051 M | 55.624 M | |
18.04% | 24.02% | 13.25% | 13.20% | 13.40% | |||
Operating income | -17.369 M | -30.315 M | -38.128 M | -43.331 M | -49.051 M | -55.624 M | |
Ebit | -17.369 M | -30.315 M | -38.128 M | -43.331 M | -49.051 M | -55.624 M | |
Pretax income | -20.064 M | -31.198 M | -37.737 M | -36.256 M | -41.437 M | -47.681 M | |
55.49% | 20.96% | -3.92% | 14.29% | 15.07% | |||
Income tax | -394.000 K | -40.000 K | -587.000 K | 1.139 M | 290.000 K | -220.000 K | |
Net income basic | -19.371 M | -31.158 M | -37.150 M | -37.694 M | -41.727 M | -47.461 M | |
-60.85% | -19.23% | -1.46% | -10.70% | -13.74% | |||
Net income | -19.371 M | -31.158 M | -37.150 M | -37.694 M | -41.727 M | -47.461 M | |
-60.85% | -19.23% | -1.46% | -10.70% | -13.74% |